Tuesday, May 11, 2021
Home Latest Pharma-News Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide

Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide

 April 21, 2021: “Novo Nordisk announced the decision to enter phase 3a development in obesity with oral semaglutide 50 mg.

The decision follows the completion of the STEP phase 3a clinical programme with once-weekly subcutaneous (sc) semaglutide 2.4 mg.

- Advertisement -

Novo Nordisk intends to initiate a pivotal phase 3a programme with approximately 1,000 people with obesity or overweight with comorbidities. The global 68-week trial is planned for initiation in the second half of 2021 and will investigate the efficacy and safety of oral semaglutide compared to placebo.

Related News: Novo-Nordisk’s semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in 68-week trial
Novo Nordisk’s wins big obesity ambitions take shape with semaglutide
Novo Nordisk invests DKK 500 million in expanding tablet production facilities in Denmark


“There is a significant unmet medical need within obesity treatment today.

With oral semaglutide we aim to introduce a convenient and effective treatment option for people with obesity and healthcare providers enabling broader use of anti-obesity medication,” said Martin Holst Lange, executive vice president, Development at Novo Nordisk.

“As a complement to our injectable anti-obesity medications, oral semaglutide has the potential to help more people living with obesity achieve weight loss goals and improve their health.”

https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=55895

LEAVE A REPLY

Please enter your comment!
Please enter your name here

five × 4 =

Most Popular

Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research

May 6, 2021: Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine. Together, the...

Imfinzi, tremelimumab combo boosts survival in lung cancer

May 07, 2021: "POSEIDON was a Phase III trial of AstraZeneca’s Imfinzi (durvalumab) plus platinum-based chemotherapy or Imfinzi, tremelimumab and chemotherapy versus chemotherapy alone in...

Vectura and Inspira Sign Agreement to Develop Potential Inhaled Treatment for COVID-19

May 06, 2021: "Vectura Group plc, an industry leading inhalation CDMO, and Inspira Pharmaceuticals Limited, a new UK-based company focused on developing therapies...

Nirsevimab MELODY Phase III trial met primary endpoint of reducing RSV lower respiratory tract infections in healthy infants

April 26, 2021: The MELODY Phase III trial for nirsevimab met its primary endpoint of a statistically significant reduction in the incidence...